Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026)

Amylyx Pharmaceuticals has reported Common Equity for 6 years, with the latest figure at $239.2 million in Q2 2026.

• On a quarterly basis, Common Equity rose 42.47% year-over-year to $239.2 million in Q2 2026; TTM through Jun 2026 was $239.2 million, a 42.47% increase from a year earlier, with the FY2025 full-year figure at $305.3 million, up 85.27% from the prior year.
• Common Equity was $239.2 million for Q2 2026 at Amylyx Pharmaceuticals, down from $273.2 million in the prior quarter.
• The five-year high for Common Equity was $433.4 million in Q4 2023, with the low at $144.0 million in Q3 2022.
• Average Common Equity over 5 years is $276.4 million, with a median of $267.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 398.83% in 2022, then plunged 61.99% in 2024.
• Over 5 years, Common Equity stood at $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then slumped by 61.99% to $164.8 million in 2024, then surged by 85.27% to $305.3 million in 2025, then retreated by 21.65% to $239.2 million in 2026.
• The last three Common Equity figures came in at $239.2 million (Q2 2026), $273.2 million (Q1 2026), and $305.3 million (Q4 2025), per Business Quant data.